Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups

This article was originally published in Start Up

Executive Summary

Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close. Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value rights (CVRs).
Advertisement

Related Content

BioMarin Refreshes Its Pipeline With ZyStor Acquisition
BioMarin Refreshes Its Pipeline With ZyStor Acquisition
Biotech Backers Learn To Live With Exit-By-Earn-Out
Biotech Backers Learn To Live With Exit-By-Earn-Out
OrbiMed Closes $550 Million Fund
Biotech Backers Are Learning to Live with Exit-by-Earn-out
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2009
Biopharma Trends: Nowhere To Go But Up
Private Biotech M&A Review: Has the Market Lost Steam?
Private Biotech M&A Review: Has the Market Lost Steam?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel